Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Sarcopenic Obesity
NCT03119610Phase 2Completed
- Start
- Sep 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in Sarcopenic Obesity (SO) (2 arms). Primary endpoint: Change in Body Weight at 8 weeks. Started Sep 2017; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Sarcopenic Obesity (SO)
Beyond the preview
Go deeper on NCT03119610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119610.